The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. David Reardon on Treating Glioblastoma Patients With EGFRvIII-Mutations

David Reardon, MD
Published Online: 5:48 PM, Fri November 20, 2015


David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, on the need to identify glioblastoma (GBM) patients with the EGFRvIII mutation in their tumor. Although this mutation is only present in roughly 30% of patients, there is a new treatment, rindopepimut (CDX-110), which has proven to be well tolerated and can improve survival in these patients. 


Reardon says it is important for community oncologists to be able to identify GBM patients with this mutation so they can receive the treatment. He says testing to identify that mutation is routinely done at most medical centers.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.